Abstract
Pimozide, a specific dopamine blocking agent, was compared with chlorpromazine in a 4-week double-blind study of the treatment of 40 schizophrenic patients newly admitted to hospital through the emergency room. Dosage was adjusted according to therapeutic effect and during the final week ranged from 10–70 mg/day (median 30 mg/day) for pimozide and 600–1,500 mg/day (median 900 mg/day) for chlorpromazine. Pimozide was found to exert somewhat less of an overall therapeutic effect than chlorpromazine, particularly in highly agitated patients. Women responded better to either treatment than men. A weighted mean of the doses given to male and female patients during the final week suggests that in the treatment of acutely ill patients the mg dose equivalency of pimozide in terms of chlorpromazine is approximately 1:25, considerably lower than estimates from maintenance studies. Pimozide induced significantly more parkinsonian symptoms but less autonomic side effects than chlorpromazine. It is suggested that the weaker presynaptic dopamine blocking effect of pimozide might be responsible for its reduced potency in the treatment of acute schizophrenic symptoms.
Similar content being viewed by others
References
Andén NW, Butcher SG, Corrodi H, Fuxe K, Ungerstedt U (1970) Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol 11:303–314
Ayd FJ (1974) Clozapine: a unique new neuroleptic. Int Drug Therapy Newsletter 9:5–12
Bunney BS, Grace AA (1978) Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci 23:1715–1728
Burnett GB, Prange AJ Jr, Wilson IC, Jolliff LA, Creese IC, Snyder SH (1980) Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. Neuropsychobiology 6:109–120
Chouinard G, Lehmann HE, Ban TA (1970) Pimozide in the treatment of chronic schizophrenic patients. Curr Ther Res 12:598–603
Chouinard G, Annable L, Ross-Chouinard A, Kropsky M (1979a) Ethopropazine and benztropine in neuroleptic-induced parkinsonism. J Clin Psychiatry 40:73–81
Chouinard G, de Montigny C, Annable L (1979b) Tardive dyskinesia and antiparkinsonian medication. Am J Psychiatry 136:228–229
Chouinard G, Ross-Chouinard A, Annable L, Jones BD (1980) Extrapyramidal symptom rating scale. Can J Neurol Sci 7:233
Clark ML, Huber WK, Hill D, Wood F, Costiloe JP (1975) Pimozide in chronic schizophrenic outpatients. Dis Nerv Syst 36:137–141
Denef C, Van Neuten JM, Leysen JE, Janssen PAJ (1979) Evidence that pimozide is not a partial agonist of dopamine receptors. Life Sci 25:217–226
Falloon I, Watt DC, Shepherd M (1978) A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med 8:59–70
Gerlach J, Reisby N, Randrup A (1974) Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacologia 34:21–35
Gerlach J, Thorsen K (1976) The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment. Int Pharmacopsychiatry 11:1–7
Gibson AC (1978) Depot injections and tardive dyskinesia. Br J Psychiatry 132:361–365
Hogarty GE, Goldberg SC, Schooler NR (1974) Drug and sociotherapy in the aftercare of schizophrenic patients. Arch Gen Psychiatry 31:609–618
Honma T, Hirose A (1979) Neuroleptic-induced changes of tyrosine hydroxylase activity in rat striatum in vitro and in vivo. Life Sci 24:2023–2030
Janssen PAJ, Niemeggers CJE, Schellekens KHL, Dresse A, Lenaerts FM, Pinchard A, Schaper WKA, Van Nueten JM, Verbruggen FJ (1968) Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug. Arzneim Forsch 18:261–279
Klawans HL, Rubovits R (1974) Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry 27:941–947
National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group (1964) Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 10:246–261
Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799–812
Overall JE, Klett CJ (1972) Applied multivariate analysis. McGraw-Hill, New York
Pinder RM, Brogden RN, Sawyer PR, Speight TM, Spencer R, Avery GS (1976) Pimozide: a review of its pharmacological properties and therepeutic uses in psychiatry. Drugs 12:1–40
Piyakulmala S, Corbet L, Ahluwalia Y, Berry RA, Meltzer HY (1977) High dose pimozide in the treatment of acutely agitated schizophrenia. Curr Ther Res 22:453–461
Raymond V, Beaulieu M, Labrie F, Boissier J (1978) Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release. Science 200:1173–1175
Shopsin B, Selzer G (1977) High-dose pimozide in acutely ill, newly admitted schizophrenic inpatients. Curr Ther Res 21:755–767
Sinha YN, Selby FW, Lewis UJ, Vanderlaan WP (1973) A homologous radioimmunoassay for human prolactin. J Clin Endocrinol Metab 36:509–516
Spitzer RL, Endicott J, Robins E (1978) Research Diagnostic Criteria, 3rd edition, Biometrics Research. New York State Psychiatric Institute, New York
Tsuang MT, Winokur G (1974) Criteria for subtyping schizophrenia. Arch Gen Psychiatry 31:43–47
Walters JR, Roth RH (1976) Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors. Arch Pharmacol 296:5–14
Wauquier A (1979) Neuroleptics and brain self-stimulation behavior. Int Rev Neurobiol 21:335–403
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chouinard, G., Annable, L. Pimozide in the treatment of newly admitted schizophrenic patients. Psychopharmacology 76, 13–19 (1982). https://doi.org/10.1007/BF00430747
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00430747